| Name | Title | Contact Details |
|---|
Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.
Segetis, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for people living with kidney disease.
The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.
Oxford Finance Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.